ArticleJHEP reports : innovation in hepatology2026
Genetic and lifestyle modifiers of haemochromatosis-related clinical outcomes in HFE C282Y homozygotes.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsThe iron overload disease haemochromatosis is primarily caused by HFE p.C282Y homozygosity, yet penetrance of clinical outcomes (including liver disease/cancer) varies. We aimed to estimate the effect of genetic and lifestyle factors on disease penetrance and expressivity in HFE C282Y homozygotes.
methodsWe analysed 2,893 C282Y homozygous UK Biobank participants (n = 1,295 male). We ascertained haemochromatosis from medical records, liver disease/cancer, osteoarthritis, joint replacement surgeries, and dementia diagnoses. We derived polygenic scores (PGS) for iron biomarkers, including hepcidin and transferrin saturation (TSAT). Sex-stratified logistic regression assessed associations with clinical outcomes. We used time-to-event regression estimating effects of age, lifestyle, and PGS, and estimated effects of rare HFE variants using whole-genome sequencing data.
resultsIn male HFE C282Y homozygotes, higher TSAT PGS increased the likelihood of diagnosis of haemochromatosis, and separately any clinical consequence (odds ratio [OR]
conclusionHigher genetically predicted TSAT significantly increased risk of clinical outcomes in HFE C282Y homozygotes. Combined with modifiable lifestyle factors, genetic information could refine risk stratification and personalise iron monitoring, following validation. IMPACT AND IMPLICATIONS: There is a pressing clinical need to understand the wide variation in clinical outcomes observed in HFE C282Y homozygotes. Higher genetically predicted TSAT significantly increased the risk of clinical outcomes, including liver and musculoskeletal complications, in HFE C282Y homozygotes, highlighting non-HFE genetic influence on disease penetrance. These results are relevant for physicians and researchers, because combining genetic factors (TSAT PGS) with demographic and lifestyle factors provided the highest prediction accuracy for haemochromatosis and related clinical outcomes. Practically, integrating polygenic risk assessments with existing patient care pathways could enhance precision therapies by enabling the earlier, targeted management of high-risk HFE C282Y homozygotes, although external validation of these predictive models is required before clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.